Febrile neutropenia: Difference between revisions

Jump to navigation Jump to search
Line 15: Line 15:
==Causes==
==Causes==
* Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of [[chemotherapy]] when it is [[myelosuppressive]] (suppresses the [[bone marrow]] from producing blood cells).
* Febrile neutropenia can develop in any form of neutropenia, but is most generally recognized as a complication of [[chemotherapy]] when it is [[myelosuppressive]] (suppresses the [[bone marrow]] from producing blood cells).
* Medication induced:[[caspofungin acetate]], [[Cyclophosphamide]]
* Medication induced:[[caspofungin acetate]], [[Cyclophosphamide]], [[Nelarabine]]


==Multinational Association for Supportive Care in Cancer (MASCC) Risk Index==
==Multinational Association for Supportive Care in Cancer (MASCC) Risk Index==

Revision as of 20:57, 16 January 2015



Resident
Survival
Guide

WikiDoc Resources for Febrile neutropenia

Articles

Most recent articles on Febrile neutropenia

Most cited articles on Febrile neutropenia

Review articles on Febrile neutropenia

Articles on Febrile neutropenia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Febrile neutropenia

Images of Febrile neutropenia

Photos of Febrile neutropenia

Podcasts & MP3s on Febrile neutropenia

Videos on Febrile neutropenia

Evidence Based Medicine

Cochrane Collaboration on Febrile neutropenia

Bandolier on Febrile neutropenia

TRIP on Febrile neutropenia

Clinical Trials

Ongoing Trials on Febrile neutropenia at Clinical Trials.gov

Trial results on Febrile neutropenia

Clinical Trials on Febrile neutropenia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Febrile neutropenia

NICE Guidance on Febrile neutropenia

NHS PRODIGY Guidance

FDA on Febrile neutropenia

CDC on Febrile neutropenia

Books

Books on Febrile neutropenia

News

Febrile neutropenia in the news

Be alerted to news on Febrile neutropenia

News trends on Febrile neutropenia

Commentary

Blogs on Febrile neutropenia

Definitions

Definitions of Febrile neutropenia

Patient Resources / Community

Patient resources on Febrile neutropenia

Discussion groups on Febrile neutropenia

Patient Handouts on Febrile neutropenia

Directions to Hospitals Treating Febrile neutropenia

Risk calculators and risk factors for Febrile neutropenia

Healthcare Provider Resources

Symptoms of Febrile neutropenia

Causes & Risk Factors for Febrile neutropenia

Diagnostic studies for Febrile neutropenia

Treatment of Febrile neutropenia

Continuing Medical Education (CME)

CME Programs on Febrile neutropenia

International

Febrile neutropenia en Espanol

Febrile neutropenia en Francais

Business

Febrile neutropenia in the Marketplace

Patents on Febrile neutropenia

Experimental / Informatics

List of terms related to Febrile neutropenia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: FN, febrile leukopenia, neutropenic fever, neutropenic fever syndrome, neutropenic sepsis, hot and low, F and N, a hot leuk

Overview

Febrile neutropenia is the development of fever, often with other signs of infection, in a patient with neutropenia, an abnormally low number of neutrophil granulocytes (a type of white blood cell) in the blood. The term neutropenic sepsis is also applied, although it tends to be reserved for patients who are less well. In 50% of cases, an infection is detectable; bacteremia (bacteria in the bloodstream) is present in approximately 20% of all patients with this condition.[1]

Causes

Multinational Association for Supportive Care in Cancer (MASCC) Risk Index

The Multinational Association for Supportive Care in Cancer (MASCC) Risk Index can be used to identify high-risk patients (score <21) and low-risk patients (score ≥21 points) for serious complications of febrile neutropenia (including death, intensive care unit admission, confusion, cardiac complications, respiratory failure, renal failure, hypotension, bleeding, and other serious medical complications).[2] The score was developed to select patients for therapeutic strategies that could potentially be more convenient or cost-effective. The various variables and the weight of individual variables used in the MASCC risk index is as follows. To summarize, risk assessment helps determining the type of empirical antibiotic therapy, venue of the treatment, and duration of the antibiotic therapy.

Characteristic Score
No or mild symptoms in patients following an episode of febrile neutropenia 5
Absence of hypotension with a systolic blood pressure >90 mmHg 5
No chronic obstructive pulmonary disease (active chronic bronchitis, emphysema, decrease in forced expiratory volumes, need for oxygen therapy and/or steroids and/or bronchodilators) 4
Solid tumor or hematologic malignancy with no previously demonstrated fungal infection or empirically treated suspected fungal infection 4
Absence of dehydration that requires parenteral fluids 3
Moderate symptoms in patients following an episode of febrile neutropenia 3
Outpatient status 3
Age <60 years 2

A prospective trial demonstrated that a modified MASCC score can identify patients with febrile neutropenia at low risk of complications as well.[3]

Treatment

Generally, patients with febrile neutropenia are treated with empirical antibiotics until the neutrophil count has recovered (Absolute neutrophil counts greater than 500/mm3) and the fever has abated; if the neutrophil count does not improve, treatment may need to continue for two weeks or occasionally more. In cases of recurrent or persistent fever, an antifungal agent should be added.

Guidelines issued in 2002 by the Infectious Diseases Society of America recommend the use of particular combinations of antibiotics in specific settings; mild low-risk cases may be treated with a combination of oral co-amoxiclav and ciprofloxacin, while more severe cases require cephalosporins with activity against Pseudomonas aeruginosa (e.g. cefepime), or carbapenems (imipenem or meropenem).[1] A subsequent meta-analysis published in 2006 found that cefepime was associated with more negative outcomes, and that carbapenems (while causing a higher rate of pseudomembranous colitis) were the most straightforward in use.[4]

In 2010, an updated guidelines was issued by the Infectious Diseases Society of America, recommending use of cefepime, carbapenems (meropenem and imipenem/cilastatin), piperacillin/tazobactam for high risk patients and co-amoxiclav and ciprofloxacin for low risk patients. Patients who do not strictly fulfill the criteria of 'low risk patients' should be admitted to the hospital and treat as high risk patients.

See also

References

  1. 1.0 1.1 Hughes WT, Armstrong D, Bodey GP; et al. (2002). "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer". Clin. Infect. Dis. 34 (6): 730–51. doi:10.1086/339215. ISSN 1058-4838. PMID 11850858. Unknown parameter |month= ignored (help)
  2. Klastersky J, Paesmans M, Rubenstein EB; et al. (16 August 2000). "The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients". J Clin Oncol. 18 (16): 3038–51. ISSN 0732-183X. PMID 10944139.
  3. de Souza Viana L, Serufo JC, da Costa Rocha MO, Costa RN, Duarte RC (2008). "Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients". Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 16 (7): 841–6. doi:10.1007/s00520-007-0347-3. ISSN 0941-4355. PMID 17960431. Unknown parameter |month= ignored (help)
  4. Paul M, Yahav D, Fraser A, Leibovici L (2006). "Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials". J. Antimicrob. Chemother. 57 (2): 176–89. doi:10.1093/jac/dki448. ISSN 0305-7453. PMID 16344285. Unknown parameter |month= ignored (help)

External links